Incapsula incident ID: 410000760008849084-25685390515639055
Shin SJ, Chung S, Kim SJ, et al
(R-KS) sent a bipartisan letter to the FDA flagging Hims & Hers' ad and accusing the company of misleading patients "by omitting any safety or side effect information when promoting a specific type of weight loss medication." Under federal law and regulations, FDA requires that prescription drug advertisements be truthful, not misleading, and balancedfailure to do so risks FDA enforcement action, including civil monetary penalties, Durbin and Marshall said in the letter
Both contain the same active ingredient (semaglutide) and work through identical mechanisms
However, the cancer death rate for pancreatic cancer has increased slightly (by 0.2% per year) since the mid-2000s according to the American Cancer Society, Cancer Facts & Figures 2022
Step four: consider compounded alternatives If brand name medications are not financially viable, compounded versions offer a significantly lower-cost pathway to continued treatment